Antifin

Quick links to important sections

Antifin

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Antifin

Quick Facts

Property Description
Active ingredient Terbinafine Hydrochloride
Pharmacological class Antifungal Agent (Antimycotic)
Origin Synthetic Compound (Allylamine derivative)
Common form Systemic (tablet) and Topical (cream, solution)
General purpose Elimination of fungal pathogens

What Type of Medicine is Antifin? (Identity and Classification)

Antifin is a synthetic medicinal compound whose active ingredient is Terbinafine Hydrochloride, and it is formally classified as a potent antifungal agent (antimycotic). This medication belongs to the chemical family of Allylamine derivatives, a class specifically engineered to address pathogenic fungi. The regulatory status of Terbinafine Hydrochloride is differentiated by its form, often being available as an Over-the-Counter (OTC) preparation for common topical issues, while systemic preparations remain Prescription-only (Rx) due to the required systemic exposure.

This compound is clinically recognized for its selective and potent fungicidal activity against a specific spectrum of dermatophytes. This classification as an antifungal agent defines its fundamental purpose: to intervene in the development and survival of these pathogens.


Composition and Available Forms of Antifin (Composition and Form)

The medicinal entity contains Terbinafine Hydrochloride as its sole active ingredient, making it a single-entity product. It is available in two major dosage form categories: systemic and topical preparations. Systemic preparations, such as tablets, are intended for internal use via the oral route of administration, targeting infections embedded deeper within the tissue. Topical preparations, including creams or solutions, are designed for direct cutaneous application for localized issues.

The availability of both forms ensures the Terbinafine Hydrochloride component can be optimally delivered, whether through absorption into the body or direct application to the skin, allowing for focused treatment based on the infection's location and nature.


Antifin's Fungicidal Action: What is its General Benefit? (High-Level Mechanism and Purpose)

The general benefit of Antifin lies in its powerful fungicidal action, meaning it actively destroys the fungal cells rather than merely halting their reproduction. This mechanism of effect involves disrupting a key enzymatic process crucial for building the fungus’s protective cell membrane.

This targeted, destructive action ensures the effective elimination of susceptible fungal pathogens, which is the primary purpose of its use in antimycotic therapy. This drug offers a focused approach to resolving infections caused by various fungal species, thereby clearing the affected tissue.

What side effects are possible with Antifin?

Possible Side Effects and Safety Information

Antifin (Terbinafine Hydrochloride, systemic) has an officially documented safety profile, categorized by regulatory agencies based on frequency and affected physiological systems. The majority of adverse reactions are associated with the oral tablet form, as confirmed by regulatory documents such as the FDA and EMA SmPC.


Adverse Reactions by Frequency and System

The most commonly documented reactions (ge 1/10 of patients) are generally gastrointestinal effects (e.g., diarrhea, dyspepsia, abdominal pain, decreased appetite), musculoskeletal reactions (arthralgia, myalgia), and skin rashes.

Less frequently, but notably, official labeling includes headache (common, ge 1/100 to <1/10), and taste disturbance (dysgeusia/ageusia), which is listed as uncommon (ge 1/1,000 to <1/100) and may contribute to weight decrease. Rare effects (ge 1/10,000 to <1/1,000) involve dizziness and hepatic dysfunction.


Serious Adverse Reactions and Safety Constraints

Official prescribing information highlights several serious adverse reactions. These include rare cases of liver failure (some leading to transplant or death), severe skin reactions (such as Stevens-Johnson syndrome or toxic epidermal necrolysis), and blood cell disorders (e.g., severe neutropenia). Furthermore, taste and smell disturbances may be prolonged or permanent.

Antifin is formally contraindicated in patients with a known history of hypersensitivity to the active ingredient or excipients, and in those with active or chronic liver disease. Its use is not recommended in individuals with severe renal impairment (creatinine clearance le 50 mL/min). Official safety requirements mandate liver function tests prior to and periodically during treatment.

Overdose and Emergency Response

Overdose Manifestations and Severity

Acute oral overdosage of Antifin (Terbinafine Hydrochloride) has been documented in regulatory reporting, including ingestions up to 5 grams. Official statements note that these high exposures have occurred without inducing serious adverse reactions. The observed clinical manifestations are generally non-severe and affect the gastrointestinal and central nervous systems. Documented signs include nausea, vomiting, abdominal or epigastric pain, headache, and dizziness.

Emergency Actions and Required Management

If an overdosage of Antifin is suspected or known, official regulatory guidance requires an immediate response. The individual must immediately contact a healthcare professional, a hospital emergency department, or a regional Poison Control Centre. This required action is mandated even in the absence of severe symptoms.

The official supportive measures described in labeling focus on eliminating the active ingredient from the body, typically through the administration of activated charcoal, and providing only symptomatic supportive therapy as clinically needed. No specific antidote for Antifin overdose is documented.

Topical Formulation Overdose

Overdose from the topical (cream or solution) formulation is considered unlikely by regulatory authorities due to the low rate of systemic absorption. Accidental ingestion of the topical preparation is generally assessed as a low-risk exposure, comparable to taking a single therapeutic oral dose.

Therapeutic Uses of Antifin

Quick Facts About Antifin's Therapeutic Use

Condition Therapeutic Domain
Fungal infections (mycoses) Supports recovery from fungal-related conditions
Superficial dermatophyte infections Addresses common skin and nail mycoses
Systemic candidiasis Utilized in the management of invasive fungal disease

What Antifin Treats: Main Uses and Benefits

Antifin is a medication prescribed to address a range of conditions stemming from fungal pathogens. Its primary purpose involves supporting the clearance of infections caused by fungi, a therapeutic domain known as antifungal treatment.

The medication is used in the clinical management of both superficial and invasive fungal conditions. This includes addressing common dermatophyte infections that may affect the skin, nails, and hair, such as tinea pedis (athlete's foot) and onychomycosis (nail fungal infections). The goal of therapy is to facilitate relief from symptoms and to assist in the resolution of the infection.

Furthermore, Antifin is also indicated for the management of more serious, systemic candidiasis in certain patient populations, which require specialized medical oversight. The agent contributes to the established treatment protocol for these internal mycoses.

Regulatory References

  1. NIH MedlinePlus guidance

Eligibility and Restrictions for Use

Population Eligibility and Contraindications

Official regulatory documents define strict criteria for who can and cannot use oral Antifin (Terbinafine Hydrochloride).

Absolute Contraindications (Must Not Use):

  • Chronic or Active Liver Disease: Use is strictly prohibited due to the risk of serious hepatic injury.
  • Hypersensitivity: Contraindicated in individuals with a known history of allergic reaction to oral terbinafine.

Restricted and Conditional Use:

Population Group Regulatory Status
Severe Renal Impairment Not recommended if creatinine clearance is leq 50 mL/min.
Pregnancy Use is not recommended, as clinical experience is very limited.
Breastfeeding Not recommended, as the drug is excreted into breast milk.
Older Adults (Geriatric) Caution is advised due to the higher probability of reduced liver or kidney function.
Systemic Lupus Erythematosus (SLE) Caution is required, as the medicine may potentially precipitate or exacerbate the condition.

Age-Related Eligibility:

Antifin is approved for use in adults for labeled indications. For children, the safety and efficacy of the oral granules are not established for those under 4 years of age. Furthermore, use of the tablets for treating nail fungus is not established in patients under 18 years of age, according to official prescribing information.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Antifin has documented interactions with other products that can significantly alter the medication’s levels or increase the risk of certain effects. These interactions generally fall into two categories: those affecting how the body processes the drug (pharmacokinetic) and those involving additive effects on the central nervous system (pharmacodynamic).

Pharmacokinetic Interactions (Metabolism-Based)

Antifin is a substrate for specific liver enzymes, primarily Cytochrome P450 (CYP) enzymes, such as CYP3A4. Therefore, its concentration in the body can be altered by products that affect these enzymes:

Product Category Interaction Mechanism Clinical Effect Restriction Status
Strong CYP Inducers (e.g., rifampin, phenytoin, St. John’s Wort) Increase enzyme activity, speeding Antifin breakdown. Significantly decreased Antifin exposure, potentially causing loss of efficacy. Contraindicated (should not be combined).
Strong CYP Inhibitors (e.g., ketoconazole, clarithromycin, grapefruit juice) Decrease enzyme activity, slowing Antifin breakdown. Significantly increased Antifin exposure, raising the risk of dose-related adverse effects. Requires dose reduction of Antifin.

Pharmacodynamic Interactions (Additive Effects)

Concomitant use of Antifin with other substances that cause central nervous system (CNS) depression can lead to enhanced effects like increased drowsiness, sedation, or impaired coordination.

  • Interacting Categories: Alcohol, opioids, benzodiazepines, and other sedating medications (e.g., certain antihistamines or tranquilizers).
  • Resulting Constraint: Co-administration with alcohol or other CNS depressants must be avoided or used with extreme caution due to the potential for compounded CNS depression, which can be severe.

Mechanism of Action

Selective Targeting of Fungal Metabolism

Antifin initiates its action by inhibiting Squalene Epoxidase (SQLE), an enzyme essential for the fungus-specific production of Ergosterol. This mechanism focuses exclusively on disrupting the Ergosterol Biosynthesis Pathway within the pathogenic cell, demonstrating high selectivity for fungal SQLE due to the unique nature of the target.

The Dual Path to Pathogen Elimination

The enzyme inhibition initiates a dual mechanistic cascade: the critical deficiency of Ergosterol required for membrane structure is combined with the toxic accumulation of Squalene—the precursor molecule—inside the cell. These combined actions result in the rapid structural failure and lysis of the fungal cell, which is the fungicidal physiological consequence that results in the elimination of the pathogen from the affected tissue. Antifin's inherent lipophilicity leads to its selective concentration in keratinous tissues (skin, nails, hair), allowing the mechanism to occur at the site of infection. However, the final biological clearance of the pathogen, particularly in slow-growing areas like the nail, is ultimately constrained by the host's tissue turnover rate, and against certain non-dermatophyte species, the mechanism may result in a fungistatic (growth-inhibition) rather than a fungicidal effect.

Dosage and Administration Information

Official Administration Guidelines for Antifin

Antifin (Terbinafine Hydrochloride) is administered through either the oral route for systemic tablets and granules or the topical route for creams and solutions, depending on the location and nature of the infection. The medication’s use is strictly defined by regulatory dosing schedules and patient-specific instructions.


Standard Labeled Dosing and Duration

Systemic treatment is standardized to 250 mg once daily for adults for approved indications. The duration of use is fixed by the infection site:

Infection Site Standard Adult Duration
Fingernail Onychomycosis 6 weeks
Toenail Onychomycosis 12 weeks (3 months)
Tinea Corporis/Cruris (Skin) 2 to 4 weeks

For topical cutaneous preparations, application is generally a thin layer applied to the affected area once or twice daily for shorter periods, such as 1 to 2 weeks for certain skin infections.


Administration Specifics and Restrictions

Oral tablets may be taken with or without food. To ensure consistent systemic levels, the tablet is taken once daily, preferably at the same time each day. If a dose is missed, it should be taken as soon as possible, unless the next scheduled dose is due soon, in which case the missed dose is skipped to avoid doubling the dose.

Official prescribing information outlines specific use restrictions for certain groups: systemic use of Antifin is not recommended in patients with chronic or active hepatic disease or significant renal impairment. Pediatric dosing for systemic use is based on body weight, typically utilizing oral granules over a fixed period, which must be sprinkled on soft, non-acidic food and swallowed without chewing.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Antifin


Research Evidence for Systemic Onychomycosis (Nail Fungus)

Research into the systemic use of Antifin for nail fungal infections, known as onychomycosis, has been primarily conducted using Randomized Controlled Trials (RCTs) and summarized in large Systematic Reviews and Meta-analyses. These studies were used in research that defined outcomes such as Mycological Cure (negative lab results for fungal presence) and Clinical Cure (visual assessment of the nail). The populations involved in this research consisted mostly of adults with confirmed infections.

Studies monitored changes measured during the study period, reporting patterns observed in the status of fungal presence and the subsequent changes in nail appearance. Because nails grow slowly, the research required long follow-up periods, sometimes extending up to a year, to assess the patterns of change and potential for the condition to return. Limited trials used a direct placebo control.


Research Evidence for Superficial Dermatophyte Infections

Antifin has also been extensively studied for common skin fungal issues, known as superficial dermatophyte infections, including Tinea Pedis, Tinea Corporis, and Tinea Cruris. Research for these infections has involved short-term RCTs and Clinical Efficacy studies. Research examined outcomes related to physical discomfort and Clinical Cure, which involved monitoring the disappearance of visible signs like scaling and redness. These studies explored short-term symptom changes, reporting measurements of fungal status shortly after the treatment phase. Follow-up durations were limited in many of these trials, and evidence for the durability of the observed outcome over many months is not as well characterized.


Research Evidence for Tinea Capitis (Scalp Fungus) and Cutaneous Candidiasis

Antifin was studied for Tinea Capitis (scalp fungus), an infection primarily requiring systemic treatment. This research focused mostly on the pediatric population (children). Studies monitored how symptoms evolved in the observed populations, with the main outcome being the Complete Cure Rate—a composite measure defined by negative lab results and clinical resolution. Evidence for use as a sole agent for the more severe, systemic forms of candidiasis remains limited, as it is mainly discussed as a contributor to established, multi-agent treatment protocols.


Research Gaps and Areas of Uncertainty

A review of the evidence highlights several areas where the research is still developing or where certainty remains low. One key limitation is that follow-up durations were limited in many studies, especially for the common, superficial skin infections, which means that the full long-term pattern of recurrence is not fully established. Furthermore, data for certain groups remain insufficient, and comparative evidence is lacking for certain head-to-head comparisons against every alternative treatment. Research is ongoing to better contextualize how patients reported their experience.

Frequently Asked Questions (FAQ)

Common questions about Antifin (FAQ)

Q: How is Antifin different from [Similar Drug Name]?

A: Official product information classifies Antifin as an allylamine antifungal agent. This chemical class is described as selectively targeting a specific enzyme in the fungal cell, which is called Squalene Epoxidase. This class-specific mechanism of action contributes to the differences between Antifin and antifungal medicines belonging to other chemical classes.

Q: Does Antifin work right away?

A: Studies indicate that while the drug is quickly absorbed into the body, it must accumulate in the infected skin and nails to exert its intended effect. Visible signs of healing, particularly for nail infections, may take many weeks. This delay is due to the natural rate of host tissue turnover, not a slow action of the medicine itself.

Q: How long does it take for Antifin to start working?

A: The medicine is designed to rapidly build up. It is described as accumulating and persisting in the affected areas. Because nails grow slowly, it may take several weeks before the antifungal effects become visibly apparent, but the active ingredient is working in the tissue from the start of therapy.

Q: Can Antifin make you tired or sleepy?

A: Official documents list dizziness as a less common side effect. Furthermore, the prescribing information notes that taking Antifin with other substances that cause central nervous system (CNS) depression can lead to enhanced effects like increased drowsiness. Tiredness or sleepiness (fatigue) is not commonly listed as a direct side effect of the medicine alone in official labeling.

Q: Does Antifin cause weight gain?

A: Regulatory safety information lists a decreased appetite as a common side effect of Antifin. It also notes that taste disturbance, which can sometimes occur, may contribute to a slight weight decrease. Weight gain is not listed as an expected reaction in the official regulatory documents.

Q: Do the side effects of Antifin go away?

A: The duration of side effects is variable. Common reactions, such as mild gastrointestinal issues, often resolve shortly after stopping treatment. However, official safety information specifies that taste and smell disturbances may be prolonged or, in rare cases, permanent.

Q: Does Antifin affect birth control pills?

A: Based on clinical studies, Antifin generally shows negligible potential for interfering with the activity of oral contraceptives. However, official regulatory reports indicate that women taking oral contraceptives while on Antifin have occasionally experienced breakthrough bleeding, and this possibility is noted in regulatory documents.

Q: Does Antifin interact with blood pressure medication?

A: Studies show that Antifin can inhibit the enzyme CYP2D6, which is part of the liver's system for processing medicines. This inhibition can potentially affect the concentration of other drug classes in the body. This includes some beta-blockers and other medications used to manage blood pressure or heart problems.

Q: What should I do if I miss a dose of Antifin?

A: For the systemic tablet, the general instruction is to take the missed dose as soon as possible, unless the next scheduled dose is due soon. If the next dose is due, the instruction is to skip the missed dose. Instructions for the topical form are generally similar, but the product label should be consulted for specific details.

Q: Can Antifin be crushed or split in half?

A: The oral granules are designed to be mixed with soft, non-acidic food and swallowed whole without chewing. Official prescribing information does not generally provide instructions for crushing or splitting the tablets. The tablets are typically taken whole as supplied.

Q: What happens if I take too much Antifin by accident?

A: Symptoms reported following accidental overdose can include nausea, vomiting, stomach pain, dizziness, rash, frequent urination, and headache. In the event of a suspected overdose, regulatory authorities state that immediate contact should be made with emergency medical services or a poison control center.

Q: How long does Antifin stay in your system?

A: While the drug is mostly cleared from the bloodstream within a few days, small amounts persist in tissues. Due to its nature, Antifin accumulates in the skin and nails and can remain in these areas for several weeks or months after the last dose, allowing the antifungal component to persist in the tissue after treatment ends.

Q: Do people typically take Antifin in the morning or evening?

A: The prescribing information states that the oral tablet should be taken once daily, preferably at the same time each day, to ensure consistent levels in the body. There is no official regulatory instruction specifying whether morning or evening administration is preferred.

Q: Is Antifin a controlled substance?

A: Antifin (Terbinafine Hydrochloride) is formally classified as a potent antifungal agent (antimycotic). It is not classified as a federally controlled substance.

Q: Is Antifin the same as a pain reliever?

A: No. Antifin is classified as an antifungal agent (antimycotic). It is not classified as a pain reliever (analgesic).

Q: Does Antifin affect my driving ability?

A: Possible side effects listed in official documents, such as dizziness and, less commonly, visual disturbances (blurred vision), may potentially affect the ability to drive or safely operate machinery. Official documents therefore advise caution.

Q: Does Antifin affect laboratory test results?

A: Yes. Official prescribing information indicates that liver function tests are required before and periodically during treatment. The medicine has also been associated with changes in certain blood parameters, including rare cases of decreased white blood cell counts and temporary changes in liver enzyme levels.

Q: Is there a generic version of Antifin available?

A: Yes. The active ingredient in Antifin is Terbinafine Hydrochloride, and this compound is widely available for prescription as a generic medicine.

Q: What should I do if I get an allergic reaction to Antifin?

A: Official safety information warns of rare but serious reactions such as severe swelling of the face, throat, or tongue, and severe skin conditions. If any sign of a severe allergic reaction occurs, regulatory documents indicate that emergency medical attention must be sought immediately, and the medicine discontinued.

Q: Is the active ingredient in Antifin available under other names?

A: Yes. The active ingredient is Terbinafine Hydrochloride. This compound is also marketed under other proprietary names, most commonly as Lamisil, in various systemic and topical forms.

Q: Is Antifin a long-term treatment or short-term?

A: Antifin is prescribed as a finite course of treatment, meaning it is taken for a defined period rather than continuously long-term. The official duration of systemic treatment is fixed by the regulatory agencies, typically lasting from 6 to 12 weeks, depending on the site of the infection.

Q: What should I do if I feel dizzy after taking Antifin?

A: Dizziness is listed as a less common adverse reaction in the regulatory documents. If dizziness or other concerning symptoms occur, official patient advice recommends stopping the medication and contacting a healthcare professional.

Q: Are there studies comparing Antifin to a placebo?

A: Yes. The efficacy of Antifin was established in research that included randomized, double-blind, placebo-controlled clinical trials. These studies were essential for establishing its approved use in treating toenail and fingernail infections (onychomycosis) and certain skin infections.

Q: Can I stop taking Antifin once I feel better?

A: Official patient information emphasizes that completing the full course of treatment as prescribed is important. This is required even if the symptoms appear to improve early, as stopping the medicine too soon may lead to the infection returning.

Q: What color are the Antifin pills?

A: Official drug identification guides and regulatory sources typically describe the standard systemic tablets containing the active ingredient, Terbinafine Hydrochloride (250 mg), as being white.

Q: Does Antifin need to be stored in the refrigerator?

A: No. Official regulatory storage instructions state that the medicine should be kept at controlled room temperature (typically 20 C to 25 C). The medication must be protected from excessive moisture and heat, but refrigeration is not required.

How should Antifin be stored and disposed of?

How to Store and Dispose of Antifin

Official regulatory documents define specific storage and disposal requirements for Antifin (Terbinafine Hydrochloride).

Storage Requirements

The medication must be stored at controlled room temperature, typically 20 C to 25 C (68 F to 77 F). It is mandatory to keep Antifin in its original container with the lid tightly closed, and it must be protected from moisture and excessive heat; therefore, storage in high-humidity areas, like a bathroom, is prohibited. For safety, the product must be kept out of the sight and reach of children and pets.

Disposal Instructions

Expired or unused Antifin should be discarded according to official instructions. The preferred method is using a drug take-back program. If this is unavailable, the medicine should be mixed with an unappealing substance, sealed in a bag, and placed in the household trash. Antifin is not on the flush list, and must not be flushed down the toilet or sink.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Antifin found in:

A-Z Index: